Pyrido[1,2-a]pyrimidine compounds, corresponding intermediates and use
申请人:Tokyo Tanabe Company, Limited
公开号:US04798832A1
公开(公告)日:1989-01-17
Pyrido[1,2-a]pyrimidine derivatives of the general formula [I] and their physiologically acceptable salts are provided: ##STR1## where R is a hydrogen atom, a halogen atom or a methyl group, and n is 0, 1 or 2. The pyrido[1,2-a]pyrimidine derivatives and their salts exhibit an excellent antagonistic effect on slow-reacting substance of anaphylaxis and, therefore, are useable for the treatment of allergic diseases.
提供了一般式为 [I] 的吡啶并[1,2-a]嘧啶衍生物及其生理上可接受的盐:##STR1## 其中 R 是氢原子、卤素原子或甲基基团,n 为0、1或2。这些吡啶并[1,2-a]嘧啶衍生物及其盐在缓慢反应性过敏物质上表现出优异的拮抗作用,因此可用于治疗过敏性疾病。
Pyrido [1,2-a] pyrimidine derivatives
申请人:TOKYO TANABE COMPANY LIMITED
公开号:EP0242230A2
公开(公告)日:1987-10-21
Pyrido[1,2-a]pyrimidine derivatives of the general formula [I] and their physiologically acceptable salts are provided:
where R is a hydrogen atom, a halogen atom or a methyl group, and n is 0, 1 or 2. The pyrido[1,2-a]pyrimidine derivatives and their salts exhibit an excellent antagonistic effect on the slow-reacting substance of anaphylaxis and, therefore, are useable for the treatment of allergic diseases.
Aqueous preparation of an pyrido[1,2-a] pyrimidine compound
申请人:TOKYO TANABE COMPANY LIMITED
公开号:EP0407000A2
公开(公告)日:1991-01-09
An aqueous preparation comprising 0.1 to 0.3 % (W/V) of a pyrido[1,2-a]pyrimidine compound represented by the following formula I:
(wherein R represents an n-propyl or allyl group; A A represents a tetrazolyl or carboxyl group; and n n represents an integer of 0 to 2),
0.5 to 2.0 % (W/V) of a polyoxyethylene sorbitan fatty acid ester, 0.5 to 2.0 % (W/V) of polyethylene glycol and 1.0 to 3.5 % (W/V) of disodium hydrogenphosphate.
一种水性制剂,包含 0.1%至 0.3%(W/V)由下式 I 代表的吡啶并[1,2-a]嘧啶化合物:
(其中 R 代表正丙基或烯丙基;A A 代表四唑基或羧基;n n 代表 0 至 2 的整数)、
0.5 至 2.0 %(W/V)的聚氧乙烯山梨糖醇脂肪酸酯、0.5 至 2.0 %(W/V)的聚乙二醇和 1.0 至 3.5 %(W/V)的磷酸氢二钠。